Poly Medicure Investing In Facilities And Products To Double International Sales

Market snapshot: Poly Medicure Limited is aggressively scaling up its manufacturing capabilities and research pipeline to double its international business revenue by fiscal year 2030. Managing Director Himanshu Baid has outlined a strategic map supported by two upcoming factories and a collection of more than 50 new clinical products.

Data Snapshot

• Consolidated operating revenue grew 12.3% YoY to ₹1,875.3 crore in FY26 from ₹1,669.8 crore in the prior fiscal year.
• International sales grew 9.3% YoY to ₹1,280.2 crore in FY26, representing nearly 68.3% of total revenue.
• Domestic sales recorded strong momentum, jumping 19.6% YoY to ₹581.7 crore in FY26 from ₹486.3 crore in FY25.
• The company's standalone operating EBITDA margin ended at 26.8%, at the upper limit of its 25% to 27% guidance range.
• Capital expenditure outlay reached ₹296 crore in FY26 to fund new capacities and product developments.

What's Changed

• Consolidated Operating Revenue increased 12.3% YoY to ₹1,875.3 crore, proving resilient despite global macroeconomic headwinds.
• Domestic sales growth of 19.6% outpaced international sales growth of 9.3%, indicating a temporary re-weighting towards India's fast-expanding market.
• The product development cycle accelerated, yielding 35 successful product launches in FY26 as part of its ongoing high-tech pivot.

Key Takeaways

• Poly Medicure is pursuing an ambitious target to double its international business by FY30, which implies reaching an export scale of roughly ₹2,560 crore.
• The roadmap relies on a 50+ pipeline of advanced products focusing on high-margin niches, including cardiology, critical care, and oncology.
• Infrastructure backup is secure, with two brand-new facilities under construction to handle the anticipated surge in production volumes.
• Geographic focus is tilting heavily towards the Global South, covering Southeast Asia, Latin America, Africa, and the Middle East to bypass traditional trade bottlenecks.

SAHI Perspective

Poly Medicure is showing strong execution in its long-term strategy to pivot from basic medical consumables into highly complex, clinically demanding medtech devices. While international growth was slightly soft at 9.3% in FY26, the underlying fundamentals are robust. By actively incorporating recent global buyouts—such as Citieffe (orthopedics) and PendraCare (cardiology)—the company has bypassed long organic R&D cycles. Its strong standalone operating EBITDA of 26.8% and net-debt free position provide ample room for continued capital investments.

Market Implications

The capacity expansion is designed to structurally decrease manufacturing costs by utilizing backward integration and outsourcing high-volume tasks to Indian facilities. This will allow the company to aggressively gain market share from multinational medtech giants in the highly underpenetrated Indian dialysis and cardiology markets, whilst defending consolidated operating margins.

Trading Signals

Market Bias: Bullish

Robust growth prospects backed by ₹296 crore capex in FY26 and a clear strategic plan to double export sales by FY30. Standalone EBITDA margins of 26.8% and high liquidity of ₹842.2 crore provide strong financial backing for global expansion.

Overweight: Healthcare Equipment, Medical Devices, Pharma Exports

Trigger Factors:

• Commercialization of the two upcoming manufacturing facilities.
• Integration and margin accretion from Citieffe and PendraCare acquisitions.
• Quarterly export growth rates crossing 15% YoY.

Time Horizon: Medium-term (3-12 months)

Industry Context

India's medical technology space is going through a rapid structural transition. Supported by localization policies, the PLI scheme, and favorable tariff adjustments in key trade pacts, domestic players are moving up the value chain. As India reduces its 70% to 80% import dependence for medical systems, localized giants like Poly Medicure are emerging as crucial suppliers in both domestic hospitals and global export corridors.

Key Risks to Watch

• Any operational delay in fully integrating Citieffe and PendraCare acquisitions might result in integration cost overruns.
• Slower-than-expected FDA or MDR approvals for the 50+ pipeline products could stretch out the target completion date.
• Increased competition from major multinational giants in highly demanding segments like renal care or vascular access.

Recent Developments

During FY26, Poly Medicure successfully launched 35 new products and spent ₹296 crore in capital expenditures. The company also announced the appointment of Indranil Mukherjee as CEO for Asia Pacific and India in June 2026 to spearhead regional growth. Additionally, integration efforts are underway for its September 2025 acquisitions of Citieffe Group (Italy) and PendraCare Group (Netherlands).

Closing Insight

Poly Medicure represents a rare blend of massive export scale and rising product complexity. Its target to double international revenue by FY30 is backed by a highly disciplined capital allocation strategy, pristine balance sheet, and structural tailwinds in India's medtech ecosystem.

High Performance Trading with SAHI.